Abstract
Background
The Hematological neoplasms (HN) are a heterogeneous group of cancers that originated in the hematopoietic or lymphoid tissues. There is reduced information published regarding HN mortality in Ecuador. This study aims to present the crude and age-specific mortality rates for HN in the Ecuadorian population.
Methods
We performed a cross-sectional study through the national database of defunctions published by the Ecuadorian National Institute of Statistics and Census, 2019. We used the ICD-10 codes to classify the HN.
Results
During 2019, 1462 deaths were reported, 53.83% were males, 87.96% of mestizo ethnicity, and 78.32% residents in urban areas. The median age was 62 years, with an interquartile range of 34.
The crude mortality rate obtained was 8.49 per 100000 inhabitants, and the higher age-specific mortality rates was 43.29 per 100000 inhabitants aged ≥ 60 years, contrasting with the 2.63 per 100000 inhabitants in people aged < 20 years. Considering each ICD-10 group, we found the following rates by 100000 inhabitants; C85 2.04, C91 1.92, C92 1.46, C90 1.11, C83 0.70, C95 0.48, C81 0.38, C84 0.16, C82 0.10, C96 0.05, C93 0.04, C86 and C94 0.02, and C88 0.01.
Conclusion
In Ecuador, during 2019, approximately eight people died due to HN by 100000 inhabitants, affecting mainly people aged ≥ 60 years. The most frequent neoplasms were Non-Hodgkin lymphomas, similar to other reports globally. These results should be analyzed considering some deficiencies in the Ecuadorian health system and the national registry. Therefore, we suggest conducting more studies regarding HN.
Keywords: Hematological neoplasm, Lymphoma, Leukemia, Observational studies, Latin America
Introduction
The term “Hematological malignancies” (HM) defines a diverse group of neoplastic diseases originated in the hematopoietic and lymphoid tissues, with a particular cytogenetic profile and clinical presentation depending each case and cell lineage [1].
In 2016 the World Health Organization published an updated version of the classification of tumors of the hematopoietic and lymphoid tissues, including more than 100 clinical entities [2].
HN represents 6.5% of all cancers globally, and particularly in Latin America, it has been observed that 57.7% of HN are represented by Non-Hodgkin Lymphoma (NHL), 29.5% Multiple Myeloma (MM), and 12.7% Chronic Lymphocytic Leukemia (CLL) [3, 4].
There is limited information regarding the mortality by HN in the Ecuadorian population. Therefore, this study aims to present the mortality analysis for these pathologies through the national registry of deaths corresponding to 2019.
Methodology
We performed an observational and cross-sectional study, reporting the crude and age-specific death rates by HN in the Ecuadorian population in 2019.
Location
Ecuador is a country located in the northwest of South America and borders Colombia to the North, the Pacific Ocean to the West, and Peru to the South and East. The country crosses the Equatorial line and has approximately 17 million inhabitants living in 283 560 km2. It is administratively divided into 24 provinces, distributed in four regions, Andean (Sierra), Coastal (Costa), Amazon (Oriente), and Insular (Galapagos) (Figure 1).
Figure 1.
Administrative Map of Ecuador
Data collection
Data were obtained from the governmental database published in 2019 [last year published] by the Ecuadorian National Institute of Statistics and Census (INEC), the last published by the institution. The information is presented by INEC in SPSS format and is freely available on their website.
The datasets analyzed during the current study are entitled “Anuario de Nacimientos y Defunciones” (https://www.ecuadorencifras.gob.ec/anuario-de-nacimientos-y-defunciones/).
As the SPSS report has data on all the deaths reported in the country during 2019, we used the ICD-10 codification to find the patients affected by hematological neoplasms.
The ICD-10 codes, which correspond to hematological neoplasms, range from C81 to C96.
For this study, we included the following information: the total number of deaths reported by hematological neoplasms each year, the total number of inhabitants each year by province, and demographic characteristics, including age, sex, and province of residence.
Calculation
We performed the statistical analysis using the software SPSS V.25 and Excel 2013. Qualitative variables were presented as percentages and quantitative variables as median values with interquartile interval.
To calculate the crude mortality rate, we used the equation:
 |
To calculate the age adjusted mortality rate, we used the equation:
 |
Years of life lost (YLL) due to premature mortality (YLLs) were calculated using the following equation: [5]
| YLL=Number of deaths by a specific HN ×Life expectancy at the age of death |
Because the database provided by INEC does not present the date of diagnosis, we cannot include the calculation of disability-adjusted life years (DALY) and years lived with disability (YLDs). As described by INEC in the document “MUJERES Y HOMBRES del Ecuador en Cifras III”, we considered life expectancy of 74.3 years for the male population and 80.2 for females.
To compare the mortality rates between regions, we used the mean differences (MD), which was presented along with confidence intervals (CI) and significance level through p-value.
Results
According to the data published by the National Institute of Statistics and Censuses (INEC), during 2019, 1462 deaths were associated with hematological neoplasms. From them, 787 (53.83%) were males, 1286 (87.96%) consider themselves to be of mestizo ethnicity, 1145 (78.32%) lived in the urban area. Additionally, the median age was 62 years, with an interquartile range (IQR) of 34. For male patients, the median age was 63 years (IQR 35), and for females, the median age was 62 years (IQR 33).
With regards to the HN diagnosed, in order of frequency, the pathologies included were diagnosed as follows; 352 (24.08%) ICD-10 C85 [Other and unspecified types of non-Hodgkin lymphoma], 330 (22.57%) ICD-10 C91 [Lymphoid leukemia], 251 (17.17%) ICD-10 C92 [Myeloid leukemia], 192 (13.13%) ICD-10 C90 [Multiple myeloma and malignant plasma cell neoplasms], and 120 (8.21%) ICD-10 C83 [Non-Follicular lymphoma] (Figure 2). The detailed results are presented in Table 1.
Figure 2.
Percentage of patients deceased classified by ICD-10 code
Table 1.
Number of patients classified according to hematological neoplasm
| ICD-10 | Hematological neoplasm | Males | Females | Total | Age | YLL males | YLL females | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | m | IQR | ||||
| C81 | Hodgkin lymphoma | 42 | 64.62 | 23 | 35.38 | 65 | 100 | 61 | 41 | 937 | 461.30 |
| C82 | Follicular lymphoma | 9 | 52.94 | 8 | 47.05 | 17 | 100 | 70 | 24.5 | 1.95 | 176.80 |
| C83 | Non-Follicular lymphoma | 60 | 50.00 | 60 | 50 | 120 | 100 | 68 | 22.5 | 827 | 1023 |
| C830 | Small cell B-cell lymphoma | 4 | 66.67 | 2 | 33.33 | 6 | 100 | 69.5 | 38.25 | 55.4 | 21.4 |
| C831 | Mantle cell lymphoma | 4 | 100.0 | 0 | 4 | 100 | 69.5 | 25 | 26.4 | ||
| C833 | Diffuse large B-cell lymphoma | 30 | 50.85 | 29 | 49.15 | 59 | 100 | 68 | 24 | 322 | 389.8 |
| C835 | Lymphoblastic lymphoma | 7 | 38.89 | 11 | 61.11 | 18 | 100 | 58.5 | 57 | 217.2 | 357.2 |
| C837 | Burkitt lymphoma | 2 | 66.67 | 1 | 33.33 | 3 | 100 | 42 | 42 | 39.2 | 38.2 |
| C839 | Other non-follicular lymphoma | 13 | 43.33 | 17 | 56.66 | 30 | 100 | 69.5 | 17.25 | 166.8 | 216.4 |
| C84 | Mature T/NK-cell lymphomas | 19 | 67.86 | 9 | 32.14 | 28 | 100 | 53 | 32.5 | 414.50 | 201.90 |
| C85 | Other and unspecified types of non-Hodgkin lymphoma | 189 | 53.69 | 163 | 46.30 | 352 | 100 | 68 | 22 | 2014.50 | 2290.30 |
| C86 | Other specified types of T/NK-cell lymphoma | 3 | 75.00 | 1 | 25 | 4 | 100 | 45.5 | 23 | 58.50 | 45.10 |
| C88 | Malignant immunoproliferative diseases | 2 | 100.0 | 0 | 0 | 2 | 100 | NC | NC | 0 | NC |
| C90 | Multiple myeloma and malignant plasma cell neoplasms | 100 | 52.08 | 92 | 47.91 | 192 | 100 | 67 | 19.5 | 694 | 1160.2 |
| C900 | Multiple myeloma | 98 | 53.26 | 86 | 46.73 | 184 | 100 | 67 | 19.75 | 631.8 | 1093.2 |
| C901 | Plasma cell leukaemia | 0 | 0.00 | 3 | 100 | 3 | 100 | 62 | 27 | 0 | 53.6 |
| C902 | Extramedullary plasmacytoma | 2 | 66.67 | 1 | 33.33 | 3 | 100 | 51 | 51 | 62.2 | 0 |
| C903 | Solitary plasmacytoma | 0 | 0.00 | 2 | 100 | 2 | 100 | NC | NC | 0 | 13.4 |
| C91 | Lymphoid leukaemia | 174 | 52.73 | 156 | 47.27 | 330 | 100 | 37.5 | 49 | 6344.8 | 5886.2 |
| C910 | Acute lymphoblastic leukaemia | 138 | 49.82 | 139 | 50.18 | 277 | 100 | 27 | 44 | 5843.8 | 5514.8 |
| C911 | Chronic lymphocytic leukaemia of B-cell type | 16 | 64.00 | 9 | 36 | 25 | 100 | 76 | 17 | 0 | 152.8 |
| C913 | Prolymphocytic leukaemia of B-cell type | 1 | 50.00 | 1 | 50 | 2 | 100 | NC | NC | 14.6 | 63.2 |
| C915 | Adult T-cell lymphoma/leukaemia | 1 | 100.0 | 0 | 1 | 100 | NC | NC | 67.6 | 0 | |
| C919 | Lymphoid leukaemia, unspecified | 18 | 72.00 | 7 | 28.00 | 25 | 100 | 418.8 | 155.4 | ||
| C92 | Myeloid leukaemia | 139 | 55.38 | 112 | 44.62 | 251 | 100 | 58 | 36 | 2614.2 | 3221.4 |
| C920 | Acute myeloblastic leukaemia | 75 | 53.57 | 65 | 46.43 | 140 | 100 | 57.5 | 34 | 1690 | 1821 |
| C921 | Chronic myeloid leukaemia, BCR/ABL-positive | 30 | 66.67 | 15 | 33.33 | 45 | 100 | 70 | 30 | 388 | 275 |
| C922 | Atypical chronic myeloid leukaemia, BCR/ABL- negative | 1 | 100.0 | 0.00 | 1 | 100 | NC | NC | 0 | 0 | |
| C923 | Myeloid sarcoma | 1 | 25.00 | 3 | 75.00 | 4 | 100 | 33.5 | 36 | 59.6 | 115.6 |
| C924 | Acute promyelocytic leukemia | 3 | 25.00 | 9 | 75.00 | 12 | 100 | 37.5 | 27 | 110.8 | 387.8 |
| C925 | Acute myelomonocytic leukaemia | 0 | 0.00 | 2 | 100.0 | 2 | 100 | NC | NC | 0 | 22.4 |
| C927 | Other myeloid leukaemia | 1 | 100.00 | 0 | 0.00 | 1 | 100 | NC | NC | 0 | 0 |
| C929 | Myeloid leukaemia, unspecified | 28 | 60.87 | 18 | 39.13 | 46 | 100 | 65 | 37.75 | 365.8 | 599.6 |
| C93 | Monocytic leukaemia | 5 | 71.43 | 2 | 28.57 | 7 | 100 | 79 | 25 | 11.5 | 4.20 |
| C946 | Myelodysplastic and myeloproliferative disease, not elsewhere classified | 2 | 66.67 | 1 | 33.33 | 3 | 100 | NC | NC | 43 | 12.10 |
| C95 | Leukaemia of unspecified cell type | 40 | 48.78 | 42 | 51.22 | 82 | 100 | 67 | 41 | 516 | 985.20 |
| C96 | Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue | 3 | 33.33 | 6 | 66.67 | 9 | 100 | 62 | 39 | 79.5 | 93.60 |
| Total | 787 | 53.83 | 675 | 46.17 | 1462 | 100 | 62 | 34 | 19761 | 12307.8 | |
ICD-10, International Classification of Diseases; m, median, IQR, interquartile range; *
Regarding age in the different neoplasms, the highest age was found in patients with ICD-10 C93 [Monocytic leukemia] with 79 years, and the lower median age corresponds to patients with ICD-10 C91, with 37.5 years. However, most patients in this group (277/330) were diagnosed with ICD-10 C91.0 [Acute lymphoblastic leukemia].
Male patients were affected more frequently in the majority of diseases, excepting ICD-10 C83.5 [Lymphoblastic lymphoma], ICD-10 C83.9 [Other non-follicular lymphoma], ICD-10 C90.1 [Plasma cell leukemia], ICD-10 C90.3 [Solitary plasmacytoma], ICD-10 C91.0 [Acute lymphoblastic leukemia], ICD-10 C92.3 [Myeloid sarcoma], ICD-10 C92.4 [Acute promyelocytic leukemia], and ICD-10 C92.5 [Acute myelomonocytic leukemia].
Mortality rates
The crude mortality rate obtained was 8.49 per 100000 inhabitants, and the age-specific mortality rates were 43.29 per 100000 inhabitants aged ≥ 60 years, 9.32 per 100000 inhabitants aged 40 to 59 years, 3.15 per 100000 inhabitants aged 20 to 39 years, and 2.63 per 100000 inhabitants aged < 20 years (Table 2). The mortality rate was significantly higher for the population with 60 years of age or more (p<0.05).
Table 2.
Crude mortality rate and age standardized rate of hematological neoplasm
| All age population | Population aged ≥ 60 years | Population aged 40 to 59 years | Population aged 20 to 39 years | Population aged < 20 years | Mortality rates | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Province code | n | % | N | % | n | % | N | % | n | % | CMR* | ASMR1* | ASMR2* | ASMR3* | ASMR4* |
| 1 | 85 | 5.8 | 55 | 6.9 | 16 | 4.9 | 6 | 3.6 | 8 | 4.8 | 9.8 | 55.7 | 9.8 | 2.1 | 2.5 |
| 2 | 23 | 1.6 | 13 | 1.6 | 9 | 2.8 | 0 | 0.0 | 1 | 0.6 | 11.0 | 49.8 | 25.0 | 0.0 | 1.1 |
| 3 | 23 | 1.6 | 13 | 1.6 | 4 | 1.2 | 2 | 1.2 | 4 | 2.4 | 8.3 | 40.9 | 8.7 | 2.3 | 3.5 |
| 4 | 18 | 1.2 | 15 | 1.9 | 2 | 0.6 | 0 | 0.0 | 1 | 0.6 | 9.7 | 64.9 | 5.1 | 0.0 | 1.5 |
| 5 | 40 | 2.7 | 20 | 2.5 | 8 | 2.5 | 9 | 5.4 | 3 | 1.8 | 8.3 | 38.4 | 9.4 | 6.3 | 1.5 |
| 6 | 37 | 2.5 | 22 | 2.8 | 4 | 1.2 | 4 | 2.4 | 7 | 4.2 | 7.1 | 33.7 | 4.2 | 2.6 | 3.4 |
| 7 | 61 | 4.2 | 35 | 4.4 | 14 | 4.3 | 6 | 3.6 | 6 | 3.6 | 8.6 | 45.8 | 9.3 | 2.7 | 2.3 |
| 8 | 37 | 2.5 | 13 | 1.6 | 7 | 2.2 | 9 | 5.4 | 8 | 4.8 | 5.8 | 23.5 | 6.4 | 4.9 | 2.8 |
| 9 | 330 | 22.6 | 155 | 19.5 | 83 | 25.5 | 40 | 24.0 | 52 | 31.1 | 7.6 | 34.0 | 8.8 | 3.0 | 3.3 |
| 10 | 60 | 4.1 | 48 | 6.0 | 1 | 0.3 | 8 | 4.8 | 3 | 1.8 | 12.8 | 88.6 | 1.1 | 5.6 | 1.7 |
| 11 | 56 | 3.8 | 35 | 4.4 | 10 | 3.1 | 5 | 3.0 | 6 | 3.6 | 10.8 | 51.5 | 10.6 | 3.3 | 3.0 |
| 12 | 56 | 3.8 | 25 | 3.1 | 14 | 4.3 | 8 | 4.8 | 9 | 5.4 | 6.1 | 28.6 | 7.8 | 3.0 | 2.4 |
| 13 | 114 | 7.8 | 61 | 7.7 | 33 | 10.2 | 9 | 5.4 | 11 | 6.6 | 7.4 | 36.1 | 10.4 | 2.0 | 1.8 |
| 14 | 10 | 0.7 | 7 | 0.9 | 0 | 0.0 | 0 | 0.0 | 3 | 1.8 | 5.2 | 53.1 | 0.0 | 0.0 | 3.2 |
| 15 | 5 | 0.3 | 4 | 0.5 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 3.8 | 42.1 | 0.0 | 2.6 | 0.0 |
| 16 | 8 | 0.5 | 5 | 0.6 | 1 | 0.3 | 0 | 0.0 | 2 | 1.2 | 7.2 | 60.9 | 5.4 | 0.0 | 4.0 |
| 17 | 346 | 23.7 | 199 | 25.0 | 75 | 23.1 | 47 | 28.1 | 25 | 15.0 | 10.9 | 56.4 | 10.8 | 4.6 | 2.3 |
| 18 | 55 | 3.8 | 29 | 3.6 | 21 | 6.5 | 3 | 1.8 | 2 | 1.2 | 9.4 | 39.9 | 17.1 | 1.6 | 1.0 |
| 19 | 8 | 0.5 | 5 | 0.6 | 1 | 0.3 | 1 | 0.6 | 1 | 0.6 | 6.8 | 54.9 | 5.4 | 2.8 | 1.8 |
| 20 | 2 | 0.1 | 0 | 0.0 | 2 | 0.6 | 0 | 0.0 | 0 | 0.0 | 6.2 | 0.0 | 27.2 | 0.0 | 0.0 |
| 21 | 3 | 0.2 | 2 | 0.3 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 1.3 | 12.3 | 0.0 | 1.4 | 0.0 |
| 22 | 7 | 0.5 | 1 | 0.1 | 3 | 0.9 | 2 | 1.2 | 1 | 0.6 | 4.4 | 10.5 | 11.4 | 4.3 | 1.3 |
| 23 | 46 | 3.1 | 21 | 2.6 | 12 | 3.7 | 2 | 1.2 | 11 | 6.6 | 10.2 | 50.9 | 13.8 | 1.4 | 6.1 |
| 24 | 32 | 2.2 | 13 | 1.6 | 5 | 1.5 | 4 | 2.4 | 10 | 6.0 | 8.2 | 35.9 | 6.7 | 3.4 | 6.1 |
| Total | 1462 | 100 | 796 | 100 | 325 | 100 | 167 | 100 | 174 | 100 | 8.5 | 43.3 | 9.3 | 3.2 | 2.6 |
ASMR1, age standardized mortality rate by population aged 60 years or more; ASMR2, age standardized mortality rate by population aged 40 to 59 years; ASMR3, age standardized mortality rate by population aged 20 to 39 years; ASMR4, age standardized mortality rate by population aged < 20 years; CMR, crude mortality rate;
*, by 100000 inhabitants.
Considering each ICD-10 group, we found the following rates by 100000 inhabitants; C85 2.04, C91 1.92, C92 1.46, C90 1.11, C83 0.70, C95 0.48, C81 0.38, C84 0.16, C82 0.10, C96 0.05, C93 0.04, C86 and C94 0.02, and C88 0.01.
Comparison between regions
The highest average mortality rate corresponds to Andean Region with 9.81 deaths by 100000 inhabitants, followed by Coastal Region (7.70/100000) and Amazon Region (4.78/100000). Mortality rates by province of residence are presented in Figure 3.
Figure 3.
Number of deceased patients (A), and crude mortality rates by province of residence (B)
The MD was significant for all comparisons, including; Andean Region vs. Coastal Region (MD -2.11, 95% CI -3.78 to -0.42, p<0.05), Andean Region vs. Amazon Region (MD -5.03, CI -7.07 to -2.99, p<0.05), and Coastal Region vs. Amazon Region (MD -2.92, CI -5.14 to -0.70, p<0.05).
Discussion
As estimated by GLOBOCAN 2018, there were 18.1 million new cases and 9.6 million cancer deaths worldwide, from which 248,724 (2.6%), 309,006 (3.2%), 106,105 (1.1%), and 26,167 (0.3%) deaths corresponds to NHL, Leukemia, MM, and Hodgkin lymphoma (HL), respectively [6].
In our study, we found that the crude mortality rate for HN was 8.49 per 100000 inhabitants, with the highest number of deceased patients corresponding to NHL, leukemia, and MM. This results are similar whit other reports presented in the region.
In Central and South America, regarding NHL, the reported age-standardized mortality rates per 100,000 varied from 1.3 to 9.2 in female patients and 1.4 to 10.9 among males [7].
In an analysis conducted through data corresponding to 17 countries from the World Health Organization, for the period 1995–2013, mortality rates were higher in male population, the highest MM mortality rates were registered in Chile (15.1/100,000 in men and 11.9/100,000 in women), and the majority of countries presented increasing trends with the highest increments in Guatemala, Ecuador, Paraguay, and Brazil [8].
In Latin America from 1990 to 2017, for AML, it has been reported that El Salvador and Ecuador had the most rapid increase in Age-Standardized Death Rate (ASDR), with estimated annual percentage changes of 3.62 (95% CI 2.93 to 4.31) and 3.53 (95% CI 3.13 to 3.93), respectively [9]. Similarly, for ALL, Andean Latin America had the fastest increase in ASDR from 1990 to 2017 (EAPC=1.59, 95% CI 1.46 to 1.72) [10].
Another relevant aspect is the small number of hematologists nationwide. According to what was presented in the 2018 Yearbook of Health Activities and Resources, 130 hematologists where registered in Ecuador for that year. In the 24 provinces, 11 did not have this specialist, and 84.62% were centralized in Pichincha (30%), Guayas (32.31%), and Manabí (22.31%). This information may explain why the Amazon region has the lowest number of deaths reported, along with the lack of availability to relevant tools such as cytogenetics, molecular biology, immunohistochemistry, PET-TC, among others. In this context, health authorities must take action to overcome the reduced access to hematology services in the majority of the provinces. Besides, there is reduced availability of bone marrow transplant (BMT) centers in Ecuador, as only one institution in Guayaquil offers this service [11]. This last aspect is preoccupying, especially when many deceased patients have HN in which BMT is the first line of treatment. Additionally, the lack of access to hematology in provinces with higher poverty rates concerns us as poverty by itself is related to increased mortality in cancer in both adults and pediatric patients [12, 13]. Similarly, some ethnic groups can be affected by this unequal distribution of access, such as indigenous communities in Coastal, Andean and Amazonic regions and the afro-descendant population located north of the Coastal region. In line with this suggestion, the association between ethnicity and poverty could also negatively impact the survival of children with acute lymphoblastic leukemia and other types of adult cancers [14, 15].
Conclusion
In Ecuador, during 2019, approximately eight people died due to HN by 100000 inhabitants, which increases to 43 defunctions by 100000 inhabitants in the population aged 60 years or more. The neoplasms with the highest number of patients deceased corresponds to Non-Hodgkin lymphomas, similar to other reports globally.
These results should be analyzed considering some deficiencies in the Ecuadorian health system as well as in the national registry, such as the reduced number of hematologists and the insufficient access to more specific diagnostic tools. Therefore, we suggest conducting more studies to understand better, how HN affects the Ecuadorian population.
Acknowledgement
None
References
- 1.Taylor J, Xiao W, Abdel-Wahab O. Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. 2017;130(4):410-423. https://doi.org/10.1182/blood-2017-02-734541 10.1182/blood-2017-02-734541 PMid: PMCid: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.de Moraes Hungria VT, Chiattone C, Pavlovsky M, et al. Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study. J Glob Oncol. 2019;5:1-19. https://doi.org/10.1200/JGO.19.00025 10.1200/JGO.19.00025 PMid: PMCid: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405. https://doi.org/10.1182/blood-2016-03-643544 10.1182/blood-2016-03-643544 PMid: [DOI] [PubMed] [Google Scholar]
- 4.Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. https://doi.org/10.1182/blood-2016-01-643569 10.1182/blood-2016-01-643569 PMid: PMCid: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Devleesschauwer B, Havelaar AH, Maertens de Noordhout C, et al. Calculating disability-adjusted life years to quantify burden of disease. Int J Public Health. 2014;59(3):565-9. https://doi.org/10.1007/s00038-014-0552-z 10.1007/s00038-014-0552-z PMid: [DOI] [PubMed] [Google Scholar]
- 6.Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492 10.3322/caac.21492 PMid: [DOI] [PubMed] [Google Scholar]
- 7.Diumenjo MC, Abriata G, Forman D, Sierra MS. The burden of non-Hodgkin lymphoma in Central and South America. Cancer Epidemiol. 2016;44 (Suppl 1):S168-S177. https://doi.org/10.1016/j.canep.2016.05.008 10.1016/j.canep.2016.05.008 PMid: [DOI] [PubMed] [Google Scholar]
- 8.Curado MP, Oliveira MM, Silva DRM, Souza DLB. Epidemiology of multiple myeloma in 17 Latin American countries: an update. Cancer Med. 2018;7(5):2101-2108. https://doi.org/10.1002/cam4.1347 10.1002/cam4.1347 PMid: PMCid: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13(1):72. https://doi.org/10.1186/s13045-020-00908-z 10.1186/s13045-020-00908-z PMid: PMCid: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Yi M, Zhou L, Li A, Luo S, Wu K. Global burden and trend of acute lymphoblastic leukemia from 1990 to 2017. Aging (Albany NY). 2020;12(22):22869-22891. https://doi.org/10.18632/aging.103982 10.18632/aging.103982 PMid: PMCid: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Garrido D, Granja M. Limitaciones en el manejo de Mieloma Múltiple en Ecuador. Rev Fac Cien Med (Quito). 2020;44(2):5-9. https://doi.org/10.29166/rfcmq.v44i2.2686 10.29166/rfcmq.v44i2.2686 [DOI] [Google Scholar]
- 12.Moss JL, Pinto CN, Srinivasan S, Cronin KA, Croyle RT. Persistent Poverty and Cancer Mortality Rates: An Analysis of County-Level Poverty Designations. Cancer Epidemiol Biomarkers Prev. 2020;29(10):1949-1954. https://doi.org/10.1158/1055-9965.EPI-20-0007 10.1158/1055-9965.EPI-20-0007 PMid: PMCid: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Byrne MM, Halman LJ, Koniaris LG, Cassileth PA, Rosenblatt JD, Cheung MC. Effects of poverty and race on outcomes in acute myeloid leukemia. Am J Clin Oncol. 2011;34(3):297-304. https://doi.org/10.1097/COC.0b013e3181dea934 10.1097/COC.0b013e3181dea934 PMid: [DOI] [PubMed] [Google Scholar]
- 14.Özdemir BC, Dotto GP. Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin? Trends Cancer. 2017;3(3):181-197. https://doi.org/10.1016/j.trecan.2017.02.002 10.1016/j.trecan.2017.02.002 PMid: PMCid: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Acharya S, Hsieh S, Shinohara ET, DeWees T, Frangoul H, Perkins SM. Effects of Race/Ethnicity and Socioeconomic Status on Outcome in Childhood Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2016;38(5):350-4. https://doi.org/10.1097/MPH.0000000000000591 10.1097/MPH.0000000000000591 PMid: [DOI] [PubMed] [Google Scholar]